Surgical site infection (SSI) causes substantial patient morbidity^[@R1]^. Since two-thirds of SSIs are confined to the incision area, much focus for SSI prevention has been on optimizing the strategy for preoperative skin antisepsis^[@R2]^. Rises in bacterial resistance^[@R3]-[@R5]^ and insufficient skin-penetration properties^[@R6]-[@R8]^ have been shown to limit the efficacy of existing skin antisepsis protocols in the prevention of SSI. As a result, there is a continuing need for alternative skin antiseptic agents, with the hope of identifying reagents with a broad spectrum of utility and adequate skin penetration and without a history of overuse or resistance.

Natural substrates with antimicrobial properties have been identified as possible sources of novel antimicrobials^[@R9]^. There is mounting evidence that the phenolic compound protocatechuic acid (PCA) functions as a broad-spectrum antimicrobial agent, including activity against drug-resistant organisms^[@R10]-[@R12]^, and demonstrates potent skin-penetration properties and deep dermal bioavailability when applied topically^[@R13],[@R14]^. In exerting their antibacterial activity, phenolic compounds have been shown to enhance the generation of reactive oxygen species in bacteria^[@R15]^ and disrupt bacterial cell-membrane integrity, causing the inhibition and leakage of intracellular contents^[@R16]^. However, most recent investigations involving PCA have focused on plant extracts, of which the exact ingredients and dosages are unknown^[@R17]-[@R19]^, limiting the feasibility for studies of potential clinical applications of the antimicrobial effects observed with this compound.

In vitro studies of natural compounds containing PCA have demonstrated its dose-dependent antimicrobial activity against several pathogens implicated in SSI, including *Cutibacterium acnes* (formerly *Propionibacterium Acnes)^[@R18]^,* a gram-positive anaerobe responsible for infections following shoulder surgery^[@R20],[@R21]^. In vivo, plant extracts containing PCA were shown to inhibit *C. acnes*-induced inflammation in mouse skin through the inhibition of lipase activity and the suppression of proinflammatory cytokines^[@R18]^. No study, to our knowledge, has examined the efficacy of topical PCA in reducing *C. acnes* bacterial loads in living skin, a particularly noteworthy consideration when evaluating its potential to prevent SSI with this pathogen.

The purpose of this proof-of-principle pilot study was to investigate the potential of PCA as a topical antimicrobial for surgical skin antisepsis. Our study aims were to (1) investigate the spectrum of antimicrobial activity of PCA, focusing on its activity against skin and wound pathogens, and (2) explore the in vivo application of PCA as a topical agent for deep, penetrating skin antisepsis using a mouse model of *C. acnes* dermal skin infection.

Materials and Methods
=====================

Antimicrobial Susceptibility Testing
------------------------------------

The Kirby-Bauer method of disc diffusion was used for the testing of antimicrobial efficacy and specificity^[@R22]^. Standard procedures recommended by the National Committee for Clinical Laboratory Standards were followed^[@R23]^. A set of discs saturated with test or control compounds were placed onto inoculated agar plates. The plates were inoculated with gram-positive, gram-negative, aerobic, and anaerobic bacteria and the fungus *Candida albicans* (see [Appendix Table 1](#app1){ref-type="sec"} for a full list of organisms included in the analysis) to determine the spectrum of antimicrobial activity of the test compounds. As we sought to identify an antimicrobial agent with the potential to reduce SSI, the primary focus of our laboratory analysis was to determine the comparative effectiveness of test compounds against *Staphylococcus aureus, Pseudomonas aeruginosa, methicillin-resistant S. aureus* (MRSA), and *C. acnes*, which are clinically challenging organisms.

The primary disinfectant used for the in vitro investigation was a 100-mM PCA solution in a water vehicle. Vanillic acid, hippuric acid, delphinidin, pelargonidin, cyanidin chloride, 28% cyanidin-3-glucoside, and 2,4,6-trihydroxybenzoic acid were also tested (at the same concentration), as they are plant secondary metabolites related to PCA. The testing of related compounds was performed to determine which compound was the likely plant secondary metabolite responsible for the antibacterial effect demonstrated in previous plant-based therapies and studies^[@R18],[@R19]^. Amoxicillin served as a positive control.

Depending on the microorganism tested, plates were incubated for 18, 24, or 48 hours. The diameters of the zones of inhibition were measured using a sliding caliper and interpreted as follows: no inhibition (NI) of growth under the test sample, inhibition (I) of growth under the test sample, no zone (NZ) of inhibition surrounding the test sample, or a clear zone (CZ) of inhibition surrounding the test sample, with the width of the clear zone (in millimeters) recorded.

Testing Against C. acnes in Mouse Skin
--------------------------------------

All experimental procedures were carried out at an independent laboratory (TransPharm Preclinical Solutions), and were performed in compliance with the laws, regulations, and guidelines of the U.S. National Institutes of Health and with the approval of the TransPharm Institutional Animal Care and Use Committee. Eight female BALB/c (Harlan) mice weighing 17 to 19 g were obtained. Each mouse was housed with 1 partner in a static cage with corn-cob bedding and had free access to food and water. Table I outlines experimental procedures and time points.

###### 

Animal Challenge, Treatment, and Harvesting Schedule[\*](#tblfn1){ref-type="table-fn"}

  Group   No.   Intradermal *C. acnes*   Treatment              Treatment Schedule[†](#tblfn2){ref-type="table-fn"}   Skin Harvest[†](#tblfn2){ref-type="table-fn"}
  ------- ----- ------------------------ ---------------------- ----------------------------------------------------- -----------------------------------------------
  1       2     6.0 log CFUs             Untreated              NA                                                    96 hr
  2       2     6.0 log CFUs             Topical PCA, 78 mM     2, 24, 48, 72 hr                                      96 hr
  3       2     6.0 log CFUs             Topical PCA, 39 mM     2, 24, 48, 72 hr                                      96 hr
  4       2     6.0 log CFUs             Topical PCA, 19.5 mM   2, 24, 48, 72 hr                                      96 hr

NA = not applicable, CFU = colony-forming unit, and PCA = protocatechuic acid.

Time defined relative to infectious challenge at 0 hour.

Mice were randomly assigned to 1 of 4 treatment groups: (1) no treatment, (2) 78 mM of topical PCA, (3) 39 mM of topical PCA, and (4) 19.5 mM of topical PCA (n = 2 mice per group). On the day before treatment, mice were anesthetized with a 5% isoflurane induction chamber and a 2.0 × 2.0-cm region on the dorsal area was cleared of hair and delineated as the infection site. *C. acnes* was selected for testing as it is responsible for the majority of shoulder SSIs^[@R20],[@R21]^, and testing against this organism may allow for some assessment of the skin-penetration properties of test reagents^[@R24]^.

Cultures of *C. acnes* (American Type Culture Collection 6919) were grown for 96 hours at 37°C, in an anaerobic atmosphere on trypticase soy (TS) agar plates supplemented with 5% sheep blood. The culture was aseptically swabbed and transferred to tubes of TS broth and allowed to grow for 72 hours. Cultures were diluted to provide an infectious inoculum of 6.0 log colony-forming units (CFUs) per 50 μL in phosphate-buffered saline (PBS) solution. On day 0, mice were again anesthetized and 50 μL of the *C. acnes* suspension was administered via intradermal injection^[@R25]^.

Following *C. acnes* inoculation, topical PCA in sterile water was administered in a dose volume of 0.1 mL at 2, 24, 48, and 72 hours post-challenge. Ninety-six hours following challenge, mice were humanely killed by carbon dioxide overexposure, and skin was aseptically removed from the infection site. Skin samples were placed in homogenization vials with 2.0 mL of PBS solution, weighed, and homogenized using a mini-bead beater. Homogenate was serially diluted and plated anaerobically on TS agar plates for the enumeration of CFUs, transformed to a decimal logarithm. To control for variations in harvested tissue weights, mean values were reported per gram of skin tissue.

Statistical Analysis
--------------------

All statistical analyses were performed using Stata (version 13.0; StataCorp). Mean (and standard deviation) bacterial burdens per gram of skin tissue were calculated and were compared between untreated mice and mice treated with each dosage of PCA using a 2-tailed t test. A p value of \<0.05 was considered significant for all tests.

Results
=======

Antimicrobial Susceptibility Testing
------------------------------------

The antimicrobial efficacies of the test compounds against *S. aureus*, *C. acnes,* MRSA, *and P. aeruginosa* are shown in Table II. Saturation with 100 mM of PCA resulted in complete zones of inhibition of at least 8 mm against each of the organisms selected for primary analysis, with the greatest activity shown against *C. acnes* (22 mm of growth inhibition). None of the other compounds tested demonstrated antimicrobial activity against all organisms. The control, amoxicillin, demonstrated growth inhibition against *S. aureus, C. acnes,* and MRSA*,* but failed to inhibit the growth of *P. aeruginosa* (see [Appendix Table 1](#app1){ref-type="sec"} for the results of the antimicrobial susceptibility testing against microbes not included in the primary analysis).

###### 

Antimicrobial Efficacy of Plant Secondary Metabolites Against Skin and Wound Pathogens[\*](#tblfn3){ref-type="table-fn"}

  Treatment (100 mM)   *S. aureus*   *C. acnes*   MRSA         *P. aeruginosa*
  -------------------- ------------- ------------ ------------ -----------------
  PCA                  I/CZ/8 mm     I/CZ/22 mm   I/CZ/9 mm    I/CZ/10 mm
  Delphinidin          I/CZ/10 mm    I/NZ         I/CZ/7 mm    NI/NZ
  Pelargonidin         I/CZ/3 mm     I/CZ/1 mm    I/CZ/4 mm    NI/NZ
  Cyanidin Cl          I/CZ/1 mm     NI/NZ        I/CZ/3 mm    NI/NZ
  28% C-3-G            I/NZ          I/CZ/23 mm   I/CZ/4 mm    I/CZ/2 mm
  2,4,6-THBA           I/CZ/13 mm    NI/NZ        I/CZ/14 mm   I/CZ/3 mm
  Vanillic acid        I/CZ/1 mm     NT           I/CZ/1 mm    I/NZ
  Hippuric acid        NI/NZ         NT           I/CZ/1 mm    NI/NZ

PCA = protocatechuic acid, I = inhibition of growth under the sample, CZ = clear zone of inhibition surrounding the sample and zone width in millimeters, NZ = no zone of inhibition surrounding the sample, NI = no inhibition of growth under the sample, Cl = chloride, C-3-G = cyanidine-3-glucoside, 2,4,6-THBA = 2,4,6-trihydroxybenzoic acid, and NT = not tested.

Antimicrobial Activity Against C. acnes
---------------------------------------

None of the mice displayed acute adverse events associated with the treatments, and no treatment group displayed adverse signs beyond those expected for mice that have received a superficial bacterial infection.

Ninety-six hours following infection, the mean bacterial burden for the untreated mice was 6.65 log CFUs per gram of skin. Compared with the untreated group, daily topical application of 78 mM of PCA was associated with a significantly lower *C. acnes* CFU burden in mice skin (mean, 5.51 log CFUs; p = 0.0295). Both lower dosages of topical PCA failed to show an effect (Table III).

###### 

*C. acnes* Mouse Skin Loads by Treatment

  Treatment      *C. acnes* Counts[\*](#tblfn4){ref-type="table-fn"}   P Value[†](#tblfn5){ref-type="table-fn"}
  -------------- ----------------------------------------------------- ------------------------------------------
  Untreated      6.65 ± 0.145                                          ---
  PCA, 78 mM     5.51 ± 0.249                                          0.0295
  PCA, 39 mM     7.5 ± 0.725                                           0.4513
  PCA, 19.5 mM   5.86 ± 0.429                                          0.2235

The values are given as the mean log CFUs (colony-forming units) per gram of skin tissue and the standard deviation.

Determined using a 2-tailed t test to compare *C. acnes* counts between untreated mice and mice treated with each dosage of PCA.

Discussion
==========

The present study was undertaken to investigate the potential of PCA as a topical antimicrobial for surgical skin antisepsis. PCA demonstrated antimicrobial efficacy in vitro against pathogens prevalent in SSI, and topical PCA demonstrated a dose-dependent reduction of *C. acnes* loads in the skin and deeper skin appendages of mice. These findings lay the groundwork for studies exploring the antimicrobial efficacy of topical PCA in human skin and provide a theoretical basis for the application of PCA as a deep, penetrating topical skin antiseptic to combat shoulder SSI.

The in vitro antimicrobial efficacy of plant-derived phytochemicals against skin and wound pathogens has been demonstrated previously. Kuete et al. demonstrated the broad-spectrum activity of PCA in a crude extract of *Ficus ovata* against gram-positive bacteria, gram-negative bacteria, and fungi, including drug-resistant organisms^[@R19]^. Liu et al. demonstrated the efficacy of PCA derived from Roselle calyx against the drug-resistant organisms MRSA, *Klebsiella pneumoniae,* and *P. aeruginosa*^[@R26]^. Lim et al. demonstrated the antibacterial activity of PCA in *Euphorbia supina* against *C. acnes*^[@R18]^. Our findings agree, as saturation with PCA resulted in clear zones of inhibition against *C. acnes* (22 mm), *S. aureus* (8 mm), MRSA (9 mm), and *P. aeruginosa* (10 mm). Through the comparison of the antimicrobial efficacy of PCA and that of related plant secondary metabolites, our results build on previous work by identifying PCA as the likely bioactive antibacterial compound contributing to the activity of these plant-based therapies against tested skin and wound pathogens.

It is estimated that up to 50.9% of SSIs in the United States are caused by microorganisms resistant to existing prophylactic antibiotics, and this rate is increasing^[@R27]^. Compared with infection with antibiotic-susceptible strains, SSI caused by resistant pathogens has consistently been linked to poorer outcomes and increased costs following orthopaedic procedures^[@R28]-[@R32]^. In the present study, PCA demonstrated activity against all tested drug-resistant organisms, including *P. aeruginosa,* MRSA, Legionella, *K. pneumoniae,* and methicillin-resistant *S. epidermidis* (MRSE). In contrast, *P. aeruginosa, K. pneumoniae,* and MRSE were unaffected by saturation with the control (see xref ref-type=\"sec\" rid=\"app1\"), amoxicillin, suggesting that some bacterial-resistance patterns developed in the presence of classic antimicrobials may not provide the same resistance to this compound. In conjunction with the extremely limited number of reported cases of microbial resistance to plant secondary metabolites^[@R33]^, these findings provide further support for investigations currently underway exploring PCA, either as monotherapy^[@R19]^ or in combination with existing antimicrobial agents^[@R34],[@R35]^, to reduce infection with drug-resistant organisms^[@R26],[@R36]^. Taken together, our laboratory investigations suggest that research into the clinical application of PCA as a skin antiseptic agent may yield promise in reducing the health-care impact of SSI.

Despite promising in vitro findings, few studies have explored in vivo applications of the antimicrobial activity of PCA. Yin and Chao demonstrated its potential as a food preservative, as PCA inhibited growth of antibiotic-resistant Campylobacter and aerobic bacteria in a dose-dependent fashion in meat^[@R37]^. The present study is the first, to our knowledge, to examine the efficacy of topical PCA at reducing *C. acnes* bacterial loads in living skin, an important therapeutic target for the prevention of SSI caused by this pathogen.

The *C. acnes* rodent injection model employed here was selected to simulate the chronic inflammatory process associated with *C. acnes* colonization in the dermis^[@R25]^, the layer of the skin where commercial preoperative antiseptic agents have been shown to provide inadequate eradication of *C. acnes*^[@R6]^. Our animal study tested the potential of PCA as a deep, penetrating topical agent to reduce dermal *C. acnes* colonization. Untreated mice demonstrated increases in *C. acnes* loads, from 6.0 log CFUs to 6.65 log CFUs, suggesting that *C. acnes* successfully established a steady intradermal colonization in the skin of BALB/c mice following injection. When administered topically, daily application of 78 mM of PCA resulted in an approximately 13.8-fold (or 1.14 log~10~) reduction in *C. acnes* CFU counts per gram of mouse skin. However, the effect was only observed at the highest dose tested. These results agree with previous findings^[@R13],[@R18]^, as the in vivo skin-penetration properties and activity of PCA against *C. acnes* were dose-dependent, suggesting that higher concentrations of topical PCA may be required to achieve antimicrobial activity against this organism in living skin.

On the basis of our current findings, the effective dose of topical PCA to reduce dermal *C. acnes* loads was 78 mM, which equates to 12.021 mg of PCA/mL. In a 100-mL volume of solution sufficient for application in human skin surrounding the shoulder joint, this would equate to an approximate dose of 1.2 g of topical PCA. It should be noted that the dose of PCA varies depending on its application and the drug vehicle^[@R10]^, and the optimal concentration and drug formulation for antimicrobial efficacy in intact human skin remain a topic of additional study. Nonetheless, our data suggest that investigations into topical PCA may yield the potential for reducing *C. acnes* loads in the dermal layer of skin. Given the relative abundance of *C. acnes* in the skin surrounding the shoulder joint and the lack of available skin antiseptic agents proven to reduce infection rates following shoulder surgery^[@R24],[@R38]^, topical PCA may serve as an attractive alternative or adjunctive agent to existing shoulder skin antisepsis protocols for the prevention of shoulder SSI. As a next step toward the potential clinical translation of these findings, our group performed a pilot study involving the human shoulder in which we explored the application of topical PCA for shoulder skin antisepsis among healthy volunteers^[@R39]^.

There were several limitations to the present study. First, amoxicillin is not used as a topical agent in clinical practice. At the initiation of the study, multiple potential applications for PCA were considered, and preliminary antimicrobial susceptibility testing against a broad spectrum of organisms (full susceptibility data in [Appendix Table 1](#app1){ref-type="sec"}) was necessary to identify the potential for PCA as a topical agent for skin disinfection. Ideally, comparisons to current skin-preparation solutions would have allowed for more robust conclusions regarding the potential of topical PCA application for skin disinfection. Another limitation relates to the small sample size in the in vivo model, predisposing our analysis to a type-II error and limiting the precision of our dosage analysis. Furthermore, only 1 microbe was examined in the in vivo model, perhaps limiting the generalizability to other pathogens of interest.

In conclusion, PCA demonstrated laboratory efficacy against pathogens implicated in SSI, including activity against drug-resistant organisms. Furthermore, topical PCA demonstrated a dose-dependent reduction in intradermal *C. acnes* burdens in a mouse model of skin infection. On the basis of our findings, studies exploring PCA as a topical antimicrobial for human skin antisepsis are warranted.

Appendix {#app1}
========

Supporting material provided by the authors is posted with the online version of this article as a data supplement at [jbjs.org](http://jbjs.org) (<http://links.lww.com/JBJSOA/A188>).
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